Cancer center tests combo therapy for aggressive blood cancer
NCT ID NCT03514017
Summary
This study tested whether combining two drugs (ibrutinib and pembrolizumab) could improve immune function and control chronic lymphocytic leukemia in high-risk patients who hadn't received prior treatment. The trial was designed to measure how well patients responded to the treatment and how long the benefits lasted. The study was terminated early after enrolling only 5 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.